Causes of oxidative stress in Alzheimer disease

Cellular and Molecular Life Sciences

Volumn 64, Issue 17, 2007, Pages 2202-2210

  Zhu, X ^a   Su, B ^a   Wang, X ^a   Smith, M A ^a   Perry, G ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b University of San Antonio   (United States)

Author keywords

Alzheimer disease; Amyloid ; Antioxidant; Iron; Metals; Mitochondria; Oxidative stress; Pathogenesis; Phosphorylation; Reactive oxygen species; Tau

Indexed keywords

COPPER; IRON;

ALZHEIMER DISEASE; ASTROCYTE; BRAIN DAMAGE; CELL ACTIVATION; GLYCATION; HUMAN; MICROGLIA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW;

ALZHEIMER DISEASE; ASTROCYTES; COPPER; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IRON; MICROGLIA; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 34548356689     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7218-4     Document Type: Review

References (125)

1. Blass, J. P. (2000) Themitochondrial spiral: an adequate cause of dementia in the Alzheimer's syndrome. Ann. N.Y. Acad. Sci. 924, 170-183.
2. Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L. and Kuhl, D. E. (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85-94.
3. Fukuyama, H., Ogawa, M., Yamauchi, H., Yamaguchi, S., Kimura, J., Yonekura, Y. and Konishi, J. (1994) Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J. Nucl. Med. 35, 1-6.
4. Hoyer, S. (1993) Intermediary metabolism disturbance in AD/SDATand its relation to molecular events. Prog. Neuropsychopharmacol. Biol. Psychiatry 17, 199-228.
5. Blass, J. P. and Gibson, G. E. (1999) Cerebrometabolic aspects of delirium in relationship to dementia. Dement. Geriatr. Cogn. Disord. 10, 335-338.
6. Castellani, R., Hirai, K., Aliev, G., Drew, K. L., Nunomura, A., Takeda, A., Cash, A. D., Obrenovich, M. E., Perry, G. and Smith, M. A. (2002) Role of mitochondrial dysfunction in Alzheimer's disease. J. Neurosci. Res. 70, 357-360.
7. Gibson, G. E., Sheu, K. F. and Blass, J. P. (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural. Transm. 105, 855-870.
8. Chandrasekaran, K., Giordano, T., Brady, D. R., Stoll, J., Martin, L. J. and Rapoport, S. I. (1994) Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res. Mol. Brain Res. 24, 336-340.
9. Cottrell, D. A., Blakely, E. L., Johnson, M. A., Ince, P. G. and Turnbull, D. M. (2001) Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57, 260-264.
10. Maurer, I., Zierz, S. and Moller, H. J. (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 21, 455-462.
11. Nagy, Z., Esiri, M. M., LeGris, M. and Matthews, P. M. (1999) Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol. 97, 346-354.
12. Parker, W. D., Jr., Mahr, N. J., Filley, C. M., Parks, J. K., Hughes, D., Young, D. A. and Cullum, C. M. (1994) Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 44, 1086-1090.
13. Parker, W. D., Jr., Parks, J., Filley, C. M. and Kleinschmidt-DeMasters, B. K. (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44, 1090-1096.
14. Zhu, X., Smith, M. A., Perry, G. and Aliev, G. (2004) Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 19, 345-352.
15. Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M. et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21, 3017-3023.
16. de la Torre, J. C. (1997) Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 43, 26-43.
17. Coskun, P. E., Beal, M. F. andWallace, D. C. (2004) Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. USA 101, 10726-10731.
18. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M. et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452.
19. Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J. and Reddy, P. H. (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437-1449.
20. Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G. and Anandatheerthavarada, H. K. (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26, 9057-9068.
21. Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. and Wolf, P. A. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346, 476-483.
22. Streck, E. L., Matte, C., Vieira, P. S., Calcagnotto, T., Wannmacher, C. M., Wajner, M. and Wyse, A. T. (2003) Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. Biochim. Biophys. Acta 1637, 187-192.
23. Connor, J. R., Milward, E. A., Moalem, S., Sampietro, M., Boyer, P., Percy, M. E., Vergani, C., Scott, R. J. and Chorney, M. (2001) Is hemochromatosis a risk factor for Alzheimer's disease? J. Alzheimers Dis. 3, 471-477.
24. Smith, M. A., Harris, P. L., Sayre, L. M. and Perry, G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci., USA 94, 9866-9868.
25. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L. and Markesbery, W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques., J. Neurol. Sci. 158, 47-52.
26. Casadesus, G., Smith, M. A., Zhu, X., Aliev, G., Cash, A. D., Honda, K., Petersen, R. B. and Perry, G. (2004) Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J. Alzheimers Dis. 6, 165-169.
27. Honda, K., Smith, M. A., Zhu, X., Baus, D., Merrick, W. C., Tartakoff, A. M., Hattier, T., Harris, P. L., Siedlak, S. L., Fujioka, H. et al. (2005) Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron., J. Biol. Chem. 280, 20978-20986.
28. Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A., Nguyen, H. U., DeMaggio, A. J., Brickman, C. M., Brewer, G. J., Dick, R. D., Troyer, M. D. et al. (1996) Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738, 265-274.
29. Castellani, R. J., Smith, M. A., Nunomura, A., Harris, P. L. and Perry, G. (1999) Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic. Biol. Med. 26, 1508-1512.
30. Mezzetti, A., Pierdomenico, S. D., Costantini, F., Romano, F., De Cesare, D., Cuccurullo, F., Imbastaro, T., Riario-Sforza, G., DiGiacomo, F., Zuliani, G. et al. (1998) Copper/zinc ratio and systemic oxidant load: effect of aging and aging-related degenerative diseases. Free Radic. Biol. Med. 25, 676-681.
31. Smith, M. A., Casadesus, G., Joseph, J. A. and Perry, G. (2002) Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33, 1194-1199.
32. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C. et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
33. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S. and Malinow, R. (2003) APP processing and synaptic function. Neuron 37, 925-937.
34. Ramsden, M., Henderson, Z. and Pearson, H. A. (2002) Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. Brain Res. 956, 254-261.
35. Ramsden, M., Plant, L. D., Webster, N. J., Vaughan, P. F., Henderson, Z. and Pearson, H. A. (2001) Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurones., J. Neurochem. 79, 699-712.
36. Nunomura, A., Perry, G., Hirai, K., Aliev, G., Takeda, A., Chiba, S. and Smith, M. A. (1999) Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann. N. Y. Acad. Sci. 893, 362-364.
37. Nunomura, A., Perry, G., Pappolla, M. A., Wade, R., Hirai, K., Chiba, S. and Smith, M. A. (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964.
38. Nunomura, A., Perry, G., Pappolla, M. A., Friedland, R. P., Hirai, K., Chiba, S. and Smith, M. A. (2000) Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59, 1011-1017.
39. Lee, H. G., Casadesus, G., Zhu, X., Takeda, A., Perry, G. and Smith, M. A. (2004) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann. N. Y. Acad. Sci. 1019, 1-4.
40. Smith, M. A., Nunomura, A., Zhu, X., Takeda, A. and Perry, G. (2000) Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal. 2, 413-420.
41. Rottkamp, C. A., Atwood, C. S., Joseph, J. A., Nunomura, A., Perry, G. and Smith, M. A. (2002) The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23, 1333-1341.
42. Rottkamp, C. A., Raina, A. K., Zhu, X., Gaier, E., Bush, A. I., Atwood, C. S., Chevion, M., Perry, G. and Smith, M. A. (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 30, 447-450.
43. Unnikrishnan, M. K. and Rao, M. N. (1990) Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone. Agents Actions 31, 110-112.
44. Hiller, K. O. and Asmus, K. D. (1981) Tl2+ and Ag2+ metalion-induced oxidation of methionine in aqueous solution: a pulse radiolysis study. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 40, 597-604.
45. Varadarajan, S., Yatin, S., Aksenova, M. and Butterfield, D. A. (2000) Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208.
46. Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S. and Beisiegel, U. (2001) Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30, 119-128.
47. Behl, C., Davis, J. B., Lesley, R. and Schubert, D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817-827.
48. Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K. and Mattson, M. P. (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68, 255-264.
49. Xu, J., Chen, S., Ahmed, S. H., Chen, H., Ku, G., Goldberg, M. P. and Hsu, C. Y. (2001) Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci. 21, RC118.
50. Mark, R. J., Pang, Z., Geddes, J. W., Uchida, K. and Mattson, M. P. (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17, 1046-1054.
51. Iversen, L. L., Mortishire-Smith, R. J., Pollack, S. J. and Shearman, M. S. (1995) The toxicity in vitro of beta-amyloid protein. Biochem. J. 311 (Pt. 1), 1-16.
52. Kontush, A. (2001) Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. Biol. Med. 31, 1120-1131.
53. Bondy, S. C., Guo-Ross, S. X. and Truong, A. T. (1998) Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 799, 91-96.
54. Schubert, D. and Chevion, M. (1995) The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 216, 702-707.
55. Huang, X., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarpa, R. C., Cuajungco, M. P., Gray, D. N., Lim, J., Moir, R. D. et al. (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry (Mosc). 38, 7609-7616.
56. Walter, M. F., Mason, P. E. and Mason, R. P. (1997) Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem. Biophys. Res. Commun. 233, 760-764.
57. Butterfield, D. A. and Bush, A. I. (2004) Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol. Aging 25, 563-568.
58. Soriani, M., Pietraforte, D. and Minetti, M. (1994) Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch. Biochem. Biophys. 312, 180-188.
59. Lynch, S. M. and Frei, B. (1997) Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochim. Biophys. Acta 1345, 215-221.
60. Harrington, C. R. and Colaco, C. A. (1994) Alzheimer's disease: a glycation connection. Nature 370, 247-248.
61. Munch, G., Thome, J., Foley, P., Schinzel, R. and Riederer, P. (1997) Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Brain Res. Rev. 23, 134-143.
62. Thome, J., Munch, G., Muller, R., Schinzel, R., Kornhuber, J., Blum-Degen, D., Sitzmann, L., Rosler, M., Heidland, A. and Riederer, P. (1996) Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci. 59, 679-685.
63. Munch, G., Schinzel, R., Loske, C., Wong, A., Durany, N., Li, J. J., Vlassara, H., Smith, M. A., Perry, G. and Riederer, P. (1998) Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural. Transm. 105, 439-461.
64. Reddy, V. P., Obrenovich, M. E., Atwood, C. S., Perry, G. and Smith, M. A. (2002) Involvement of Maillard reactions in Alzheimer disease. Neurotox. Res. 4, 191-209.
65. Smith, M. A., Sayre, L. M., Monnier, V. M. and Perry, G. (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci. 18, 172-176.
66. Smith, M. A., Richey, P. L., Taneda, S., Kutty, R. K., Sayre, L. M., Monnier, V. M. and Perry, G. (1994) Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 738, 447-454.
67. Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K. and Cerami, A. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 4766-4770.
68. Smith, M. A., Rudnicka-Nawrot, M., Richey, P. L., Praprotnik, D., Mulvihill, P., Miller, C. A., Sayre, L. M. and Perry, G. (1995) Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64, 2660-2666.
69. Shuvaev, V. V., Laffont, I., Serot, J. M., Fujii, J., Taniguchi, N. and Siest, G. (2001) Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22, 397-402.
70. Smith, M. A., Taneda, S., Richey, P. L., Miyata, S., Yan, S. D., Stern, D., Sayre, L. M., Monnier, V. M. and Perry, G. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91, 5710-5714.
71. Li, J. J., Surini, M., Catsicas, S., Kawashima, E. and Bouras, C. (1995) Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging 16, 69-76.
72. Ko, L. W., Ko, E. C., Nacharaju, P., Liu, W. K., Chang, E., Kenessey, A. and Yen, S. H. (1999) An immunochemical study on tau glycation in paired helical filaments. Brain Res. 830, 301-313.
73. Castellani, R. J., Harris, P. L., Sayre, L. M., Fujii, J., Taniguchi, N., Vitek, M. P., Founds, H., Atwood, C. S., Perry, G. and Smith, M. A. (2001) Active glycation in neurofibrillary pathology of Alzheimer disease:N(epsilon)- (carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 31, 175-180.
74. Mruthinti, S., Sood, A., Humphrey, C. L., Swamy-Mruthinti, S. and Buccafusco, J. J. (2006) The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products. Neuroscience 142, 463-473.
75. Yan, S. D., Roher, A., Chaney, M., Zlokovic, B., Schmidt, A. M. and Stern, D. (2000) Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim. Biophys. Acta 1502, 145-157.
76. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J. et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
77. El Khoury, J., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C. and Loike, J. D. (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382, 716-719.
78. Eikelenboom, P. andVeerhuis, R. (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17, 673-680.
79. Mrak, R. E., Sheng, J. G. and Griffin, W. S. (1996) Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol. Exp. Neurol. 55, 273-279.
80. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
81. Van Muiswinkel, F. L., Veerhuis, R. and Eikelenboom, P. (1996) Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J. Neurochem. 66, 2468-2476.
82. Klegeris, A. and McGeer, P. L. (1997) beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res. 49, 229-235.
83. Good, P. F., Werner, P., Hsu, A., Olanow, C. W. and Perl, D. P. (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149, 21-28.
84. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S. and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
85. Luth, H. J., Munch, G. and Arendt, T. (2002) Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. 953, 135-143.
86. Luth, H. J., Holzer, M., Gartner, U., Staufenbiel, M. and Arendt, T. (2001) Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 913, 57-67.
87. Reynolds, W. F., Rhees, J., Maciejewski, D., Paladino, T., Sieburg, H., Maki, R. A. and Masliah, E. (1999) Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp. Neurol. 155, 31-41.
88. Podrez, E. A., Schmitt, D., Hoff, H. F. and Hazen, S. L. (1999) Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547-1560.
89. Anderson, M. M., Requena, J. R., Crowley, J. R., Thorpe, S. R. and Heinecke, J. W. (1999) Themyeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)-lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 104, 103-113.
90. Glickman, M. H. and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428.
91. Reinheckel, T., Ullrich, O., Sitte, N. and Grune, T. (2000) Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch. Biochem. Biophys. 377, 65-68.
92. Keller, J. N., Gee, J. and Ding, Q. (2002) The proteasome in brain aging. Ageing Res. Rev. 1, 279-293.
93. Perry, G., Friedman, R., Shaw, G. and Chau, V. (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA 84, 3033-3036.
94. Hol, E. M., van Leeuwen, F. W. and Fischer, D. F. (2005) The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. Trends Mol. Med. 11, 488-495.
95. Keller, J. N., Hanni, K. B. and Markesbery, W. R. (2000) Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436-439.
96. Keller, J. N. and Markesbery, W. R. (2000) Proteasome inhibition results in increased poly-ADP-ribosylation: implications for neuron death. J. Neurosci. Res. 61, 436-442.
97. McNaught, K. S., Mytilineou, C., Jnobaptiste, R., Yabut, J., Shashidharan, P., Jennert, P. and Olanow, C. W. (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301-306.
98. Sullivan, P. G., Dragicevic, N. B., Deng, J. H., Bai, Y., Dimayuga, E., Ding, Q., Chen, Q., Bruce-Keller, A. J. and Keller, J. N. (2004) Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J. Biol. Chem. 279, 20699-20707.
99. Ding, Q., Dimayuga, E., Martin, S., Bruce-Keller, A. J., Nukala, V., Cuervo, A. M. and Keller, J. N. (2003) Characterization of chronic low-level proteasome inhibition on neural homeostasis. J. Neurochem. 86, 489-497.
100. Ding, Q., Reinacker, K., Dimayuga, E., Nukala, V., Drake, J., Butterfield, D. A., Dunn, J. C., Martin, S., Bruce-Keller, A. J. and Keller, J. N. (2003) Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett. 546, 228-232.
101. Radisky, D. C. and Kaplan, J. (1998) Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem. J. 336 ( Pt 1), 201-205.
102. Brunk, U. T., Neuzil, J. and Eaton, J. W. (2001) Lysosomal involvement in apoptosis. Redox Rep. 6, 91-97.
103. Zhao, M., Antunes, F., Eaton, J. W. and Brunk, U. T. (2003) Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur. J. Biochem. 270, 3778-3786.
104. Nakamura, Y., Takeda, M., Suzuki, H., Hattori, H., Tada, K., Hariguchi, S., Hashimoto, S. and Nishimura, T. (1991) Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease. Neurosci. Lett. 130, 195-198.
105. Cataldo, A. M., Thayer, C. Y., Bird, E. D., Wheelock, T. R. and Nixon, R. A. (1990) Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res. 513, 181-192.
106. Cataldo, A. M., Hamilton, D. J. and Nixon, R. A. (1994) Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 640, 68-80.
107. Cataldo, A. M., Paskevich, P. A., Kominami, E. and Nixon, R. A. (1991) Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl. Acad. Sci., USA 88, 10998-11002.
108. Bernstein, H. G., Kirschke, H., Wiederanders, B., Schmidt, D. and Rinne, A. (1990) Antigenic expression of cathepsin B in aged human brain. Brain Res. Bull. 24, 543-549.
109. Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A. and Cuervo, A. M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113-122.
110. Gray, D. A. and Woulfe, J. (2005) Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowledge Environ 2005, re1.
111. Brunk, U. T. and Terman, A. (2002) The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur. J. Biochem. 269, 1996-2002.
112. Brunk, U. T., Jones, C. B. and Sohal, R. S. (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mutat. Res. 275, 395-403.
113. Smith, M. A., Taneda, S., Richey, P. L., Miyata, S., Yan, S. D., Stern, D., Sayre, L. M., Monnier, V. M. and Perry, G. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91, 5710-5714.
114. Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R. and Butterfield, D. A. (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1394-1401.
115. Williamson, K. S., Gabbita, S. P., Mou, S., West, M., Pye, Q. N., Markesbery, W. R., Cooney, R. V., Grammas, P., Reimann-Philipp, U., Floyd, R. A. and Hensley, K. (2002) The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6, 221-227.
116. Butterfield, D. A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
117. Markesbery, W. R. and Lovell, M. A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33-36.
118. Lovell, M. A., Ehmann, W. D., Butler, S. M. and Markesbery, W. R. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
119. Tamaoka, A., Miyatake, F., Matsuno, S., Ishii, K., Nagase, S., Sahara, N., Ono, S., Mori, H., Wakabayashi, K., Tsuji, S. et al. (2000) Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 54, 2319-2321.
120. Palmer, A. M. and Burns, M. A. (1994) Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645, 338-342.
121. Guan, Z., Wang, Y., Cairns, N. J., Lantos, P. L., Dallner, G. and Sindelar, P. J. (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58, 740-747.
122. Sayre, L. M., Zelasko, D. A., Harris, P. L., Perry, G., Salomon, R. G. and Smith, M. A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092-2097.
123. Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A. and Markesbery, W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA 88, 10540-10543.
124. Smith, M. A., Richey, P. L., Taneda, S., Kutty, R. K., Sayre, L. M., Monnier, V. M. and Perry, G. (1994) Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 738, 447-454.
125. Smith, M. A., Perry, G., Richey, P. L., Sayre, L. M., Anderson, V. E., Beal, M. F. and Kowall, N. (1996) Oxidative damage in Alzheimer's. Nature 382, 120-121.